TacticScaleWhat Jazz Pharmaceuticals Does & How It Makes Money (JAZZ)
Updated October 2026 · reflects Jazz Pharmaceuticals's latest reported financials
Irish biopharma selling sleep, epilepsy, and cancer medicines. Jazz earns revenue by selling its approved branded drugs for sleep, epilepsy, and cancer, mostly specialty medicines for small patient groups.
How Jazz Pharmaceuticals makes money
Jazz earns revenue by selling its approved branded drugs for sleep, epilepsy, and cancer, mostly specialty medicines for small patient groups. It adds to its pipeline through in-house research and partnerships with other biotech companies.
What Jazz Pharmaceuticals does
Jazz Pharmaceuticals is a Dublin-based biopharmaceutical company focused on neuroscience and oncology. In neuroscience, it sells Xywav for cataplexy and excessive daytime sleepiness in narcolepsy and idiopathic hypersomnia, and Epidiolex for seizures linked to Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Its oncology products include Rylaze and Enrylaze for acute lymphoblastic leukemia, Zepzelca for metastatic small cell lung cancer, Ziihera for HER2-positive biliary tract cancer, Modeyso for H3 K27M-mutant diffuse midline glioma, and Defitelio for severe veno-occlusive disease. Much of its growth pipeline is in cancer. Zanidatamab is in Phase 3 for HER2-positive gastroesophageal and biliary tract cancers and is also being studied in breast cancer. Vyxeos is being tested in more types of AML and high-risk MDS, and earlier-stage programs such as JZP3507, JZP815, JZP898, and JZP047 are in development. Jazz uses partnerships with Zymeworks, Redx, Sumitomo Pharma, Werewolf, AbCellera, and Autifony to add new drug candidates.
Products & services
- Xywav
- Epidiolex
- Zepzelca
- Rylaze
- Ziihera (zanidatamab)
- Defitelio
What is Jazz Pharmaceuticals worth?
On an owner-earnings DCF, Jazz Pharmaceuticals's most-likely value is about $413 versus a recent price near $218 (89% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$240) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Harmony Biosciences (HRMY) · Alkermes (ALKS) · Bristol-Myers Squibb (BMY) · Neurocrine Biosciences (NBIX) · Supernus Pharmaceuticals (SUPN)